Key Points
- Director sale: Hollings Renton sold 5,000 AnaptysBio shares for approximately $249,350 under a pre-arranged Rule 10b5-1 plan, reducing direct ownership by 31.26% to 10,995 shares.
- Quarterly results exceeded expectations: AnaptysBio reported $5.11 in quarterly EPS versus consensus estimates for a $0.46 loss, while revenue of $27.49 million surpassed the $14.06 million forecast.
- Analyst sentiment remains positive: The stock has a “Moderate Buy” consensus rating from analysts, with an average price target of $77.79 versus its recent opening price of $48.53.
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Hollings Renton sold 5,000 shares of the firm's stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $49.87, for a total transaction of $249,350.00. Following the completion of the transaction, the director directly owned 10,995 shares in the company, valued at $548,320.65. This represents a 31.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
AnaptysBio Trading Down 0.2%
ANAB stock opened at $48.53 on Friday. AnaptysBio, Inc. has a 12-month low of $19.65 and a 12-month high of $72.36. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of 9.04 and a beta of 0.76. The business's 50-day moving average is $55.04 and its 200 day moving average is $58.62.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Monday, September 21st. The biotechnology company reported $5.11 EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $5.57. The business had revenue of $27.49 million during the quarter, compared to analysts' expectations of $14.06 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%.During the same quarter in the prior year, the firm earned ($1.30) earnings per share. As a group, equities analysts forecast that AnaptysBio, Inc. will post -1.3 EPS for the current fiscal year.
Institutional Trading of AnaptysBio
Several large investors have recently added to or reduced their stakes in the stock. Persistent Asset Partners Ltd purchased a new position in shares of AnaptysBio during the 2nd quarter worth $39,000. Caitong International Asset Management Co. Ltd boosted its position in shares of AnaptysBio by 940.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company's stock valued at $74,000 after acquiring an additional 1,383 shares during the last quarter. Group One Trading LLC acquired a new position in shares of AnaptysBio during the 2nd quarter valued at about $140,000. State of Wyoming purchased a new stake in shares of AnaptysBio in the second quarter valued at about $158,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of AnaptysBio in the first quarter valued at about $205,000.
Analyst Ratings Changes
Several research firms recently commented on ANAB. Wall Street Zen raised AnaptysBio from a "hold" rating to a "buy" rating in a research note on Saturday, September 26th. Scotiabank cut shares of AnaptysBio to a "hold" rating and set a $70.00 target price on the stock. in a research note on Tuesday, August 25th. Leerink Partners lowered their target price on shares of AnaptysBio from $90.00 to $81.00 and set an "outperform" rating on the stock in a research note on Wednesday, September 23rd. HC Wainwright reaffirmed a "buy" rating and set a $95.00 target price on shares of AnaptysBio in a report on Tuesday, September 22nd. Finally, JPMorgan Chase & Co. reduced their target price on shares of AnaptysBio from $70.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $77.79.
Read Our Latest Analysis on AnaptysBio
AnaptysBio Company Profile
(
Get Free Report)
AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for inflammatory and autoimmune diseases. The company uses its antibody discovery and engineering capabilities to identify therapies designed to modulate immune-system targets involved in disease.
AnaptysBio's pipeline has included rosnilimab, an investigational antibody designed to target CD200R1, a receptor involved in regulating immune-cell activity. The company has evaluated rosnilimab in inflammatory and autoimmune conditions, including rheumatoid arthritis and ulcerative colitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
